OTC Drug Spending By Some Insurers Hindered By Antitrust Law
This article was originally published in The Tan Sheet
Statutory caps on nonprescription drug spending by not-for-profit insurers could pose a significant barrier to expanded use of over-the-counter products
You may also be interested in...
A pharmacy "fee-for-service" model could create a "de facto third class" of drugs that would facilitate over-the-counter switches for chronic-use medications, SDM, Inc. President Bill Howard, PhD, suggested at an IIR conference on Rx-to-OTC switches in Philadelphia Nov. 20
Bristol-Myers Squibb's Pravachol (pravastatin) 10 mg is an attractive candidate for OTC status, but the company should first conduct additional label comprehension studies and better define the target population for the cholesterol agent, FDA advisory committee members suggested July 14.
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC